Henry Schein Inc banner

Henry Schein Inc
XMUN:HS2

Watchlist Manager
Henry Schein Inc Logo
Henry Schein Inc
XMUN:HS2
Watchlist
Price: 76.75 EUR 0.66% Market Closed
Market Cap: €10B

Henry Schein Inc
Investor Relations

Henry Schein is a distributor and service provider for dental and medical practices. It sells everyday consumable supplies, lab products, instruments, and larger equipment that clinics use to treat patients, along with software and business services that help offices run smoothly. It sits in the middle of the healthcare supply chain, moving products from manufacturers to small and mid-sized practices that need a one-stop source. Its main customers are dentists, dental labs, animal health practices, and physician offices, with dentistry as the company’s core market. Henry Schein makes money by buying products from manufacturers and reselling them to customers, while also earning fees from equipment service, practice management software, and related support services. Because many customers rely on regular replenishment and ongoing technical help, a lot of its business is repeat and relationship-based. What makes Henry Schein different is the mix of distribution and hands-on practice support. It does not just ship boxes of supplies; it also helps customers choose equipment, install it, maintain it, and manage parts of their office workflow. That makes the company more than a wholesaler and gives it a practical role in helping independent healthcare practices operate day to day.

Show more
Loading...
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Aug 4, 2026
AI Summary
Q2 2026

Quarter: Henry Schein said second-quarter results were strong, with sales up 6.7% to $3.5 billion and earnings growth supported by better margins and early value-creation benefits.

Guidance: Management raised full-year 2026 guidance for both sales and EPS, but kept a conservative stance by excluding any further remeasurement gains.

Growth drivers: Dental merchandise, technology, specialty products and Home Solutions all contributed, while U.S. equipment was softer because of tough comparisons from last year’s large dental school orders.

Value creation: The company said its cost and operating initiatives remain on track for more than $200 million of operating income improvement over the next few years, with a $125 million run rate targeted by the end of 2026.

Strategy: New CEO Frederick Lowery emphasized faster decision-making, simplification, deeper customer relationships and a bigger role for AI-enabled software in driving future growth.

Key Financials
Sales
$3.5 billion
Internal local currency sales growth
4.6%
GAAP operating margin
4.94%
Operating margin
7.21%
GAAP net income
$94 million
GAAP diluted EPS
$0.82
Net income
$145 million
Diluted EPS
$1.27
Adjusted EBITDA
$288 million
Operating cash flow
$242 million
Shares repurchased
2.6 million
Share repurchase spend
$200 million
Authorization remaining
$455 million
Restructuring expenses
$29 million
Dentrix Ascend and Dentale customers
almost 13,000
Henry Schein One revenue recurring mix
approximately 90%
Average monthly revenue per Henry Schein One customer
approximately $500
Average monthly revenue per Dentrix Ascend customer
approximately $800
Value creation operating income improvement goal
more than $200 million
Value creation run rate target
$125 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Stanley M. Bergman CPA
Executive Chairman & CEO
No Bio Available
Mr. James P. Breslawski CPA
President
No Bio Available
Mr. Ronald N. South
Senior VP & CFO
No Bio Available
Mr. Michael Saul Ettinger
Executive VP & COO
No Bio Available
Mr. Mark E. Mlotek
Executive VP, Chief Strategic Officer & Executive Director
No Bio Available
Ms. Olga Timoshkina
VP of Corporate Finance, Chief Accounting Officer & Corporate Controller
No Bio Available
Mr. Christopher Pendergast
Senior VP & CTO
No Bio Available
Mr. Graham Stanley
VP of Investor Relations & Strategic Finance Project Officer
No Bio Available
Mr. Walter Siegel
Senior VP & Chief Legal Officer
No Bio Available
Ms. Ann Marie Gothard
Vice President of Global Corporate Media Relations
No Bio Available

Contacts

Address
NEW YORK
Melville
135 Duryea Rd
Contacts